# US 2017/0253657 A1 · Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253657 A1
- Document ID: US20170253657A1
- Status: Published application
- Kind: A1
- Application number: 15/602,659
- Filed: 2017-05-23
- Published: 2017-09-07
- Earliest claimed: 2013-10-03
- Assignees: Leuvas Therapeutics
- Applicants: Leuvas Therapeutics
- Inventors: Gabriela Constantin
- Web page: https://patentgrep.com/patent/US20170253657A1

## CPC

- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2821: {against ICAM molecules, e.g. CD50, CD54, CD102}
- C07K 16/2836: {against CD106}
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells into the brain, by reducing motility of neutrophil/myeloid cells in the parenchyma, by blocking Aβ-induced activation and adhesion of neutrophil/myeloid cells, and/or by blocking Aβ-induced integrin activation, degranulation and/or ROS release in neutrophil/myeloid cells.

## Claims

### Claim 1

A method of prevention and treatment of neurodegenerative disease in an individual mammal, said method comprising:
administering to said individual mammal an effective amount of an agent that reduces the presence or activity of myeloid cells and/or neutrophils in the brain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the treatment reduces development of cognitive deficits in the mammal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the individual is diagnosed with AD prior to treatment.

### Claim 5 (depends on 4)

The method of claim 4, wherein the individual is differentially diagnosed with AD.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammal is a rodent that provides a model for AD.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agent has an activity selected from: (i) depletion of neutrophil/myeloid cell populations systemically or locally in the brain; (ii) blocking neutrophils/myeloid cell adhesion and crawling; (iii) blocking transmigration and infiltration of neutrophils/myeloid cells into the brain; (iv) blocking cell-cell interactions between neutrophil/myeloid cells and endothelial cells and/or neural cells; (v) blocking neutrophil/myeloid cell extracellular-matrix interactions; (vi) reducing motility of neutrophils/myeloid cells in the brain parenchyma; (vii) blocking Aβ-induced activation and adhesion of neutrophils/myeloid cells; (viii) blocking intracellular signaling controlling adhesion and activation; (ix) blocking neutrophil activation and/or degranulation; (x) blocking release of reactive oxygen species, proteases, cytokines, lipid mediators or other damaging agents from myeloid cells and/or neutrophils; (xi) blocking neutrophil/myeloid cell activation leading to increased affinity and valency; (xii) blocking formation of neutrophil extracellular traps (NETS) in brain vessels or parenchyma; (xiii) blocking neurodegenerative processes including synaptic dysfunction and/or degradation; (xiv) reducing activation and/or number of microglial cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent inhibits the interaction between an adhesion molecule involved in leukocyte trafficking or extravasation and a ligand for the adhesion molecule.

### Claim 10 (depends on 9)

The method of claim 9, wherein the adhesion molecule is selected from ICAM-1, LFA-1, CD11a, CD11b, CD11c, CD18, alpha-4 integrin, E-selectin, P-selectin and L-selectin.

### Claim 11 (depends on 9)

The method of claim 9, wherein the ligand is selected from VCAM-1, MAdCAM-1, CD49; PSGL-1, CD44, CD43, and hyaluronan.

### Claim 12 (depends on 8)

The method of claim 8, wherein the agent depletes neutrophil/myeloid cell populations systemically, or locally in the brain.

### Claim 13 (depends on 8)

The method of claim 8, wherein the agent inhibits activity of a protein tyrosine kinase involved in leukocyte activation or trafficking.

### Claim 14 (depends on 13)

The method of claim 13, wherein the protein tyrosine kinase is selected from Syk, Abl, JAK3, Jak2, and BTK and MAPK; and PI3K.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claim 1-14, wherein the agent does not cross the blood brain barrier after administration.

### Claim 16 (depends on 1)

The method of claim 1, wherein the efficacy of treatment is tracking by monitoring one or more biomarkers selected from (i) the number of circulating neutrophils/myeloid cells and/or ratio of circulating neutrophils/myeloid cells and other leukocytes; (ii) the number of brain-resident neutrophils/myeloid cells; (iii) activation status of circulating neutrophils/myeloid cells; (iv) activation status of brain-resident neutrophils/myeloid cells; (v) adhesion capability of circulating neutrophils/myeloid cells; (vi) adhesion capability of brain-resident neutrophils/myeloid cells; (vii) inflammatory markers in blood; (viii) inflammatory markers in cerebrospinal fluid; (ix) neurodegenerative markers in cerebrospinal fluid.

### Claim 17 (depends on 16)

The method of claim 16, wherein monitoring is performed at multiple time points.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A kit for use in the methods of any one of claims 1-17, comprising an agent and instructions for use.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A unit dose of a medicament for us in the methods of any one of claims 1-17.
